All articles tagged: Unspecified B-cell lymphoma (C85.1)


HealthDay 21 December at 04.47 PM American Society of Hematology, Dec. 9 to 12 The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and # Hematology & Oncology 0 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
HealthDay 12 December at 03.58 PM ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual # Hematology & Oncology 0 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn

HealthDay 21 December at 04.47 PM

American Society of Hematology, Dec. 9 to 12

The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and

# Hematology & Oncology

0 Likes

0 Comments

HealthDay 12 December at 03.58 PM

ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients

For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual

# Hematology & Oncology

0 Likes

0 Comments


Medical xPress 05 July at 07.10 AM When it comes to male life expectancy, nature and nurture work together Although the simple biological fact (nature) of being born male increases boys' and men's overall health risks, the behavioral choices (nurture) they make are at least as important. This means that trans men and others who identify as men, while not biologically male, may also experience the behavioral disadvantages of being male. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 05 July at 06.50 AM Study explores the link between stock market fluctuations and emergency room visits in China The advent of computerized trading and fintech platforms has made investing in stocks easier and more accessible to individuals worldwide. This has led to an increase in stock market participation in many countries, including China. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 30 June at 07.40 AM Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts say Intrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
HealthDay 27 June at 03.19 PM Immunoglobulin Replacement Therapy Beneficial for Blood Cancers Immunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medpage Today 26 June at 04.59 PM When Was the Last Time You Really Talked With Your Patient? My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medpage Today 23 June at 09.21 PM Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2D ORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn

Medpage Today 22 June at 06.00 PM Fenofibrate Slows Diabetic Retinopathy Progression ORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medpage Today 22 June at 06.00 PM Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic Stroke TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 22 June at 05.20 PM Lawsuit could challenge trust in Ozempic and other popular weight loss drugs The manufacturers of the most popular weight loss drugs are being challenged in court. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
HealthDay 21 June at 03.38 PM Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low The overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn